Erschienen: 23.08.2016 Abbildung von Antonijevic | Optimization of Pharmaceutical R&D Programs and Portfolios | Softcover reprint of the original 1st ed. 2015 | 2016 | Design and Investment Strategy

Antonijevic

Optimization of Pharmaceutical R&D Programs and Portfolios

Design and Investment Strategy

lieferbar ca. 10 Tage als Sonderdruck ohne Rückgaberecht

106,99 €

inkl. Mwst.

Softcover reprint of the original 1st ed. 2015 2016. Buch. viii, 202 S. 14 s/w-Abbildungen, 24 Farbabbildungen, 17 s/w-Tabelle, 10 Farbtabellen, Bibliographien. Softcover

Springer. ISBN 978-3-319-34312-9

Format (B x L): 15,5 x 23,5 cm

Gewicht: 332 g

In englischer Sprache

Produktbeschreibung

Very little has been published on optimization of pharmaceutical portfolios. Moreover, most of published literature is coming from the commercial side, where probability of technical success (PoS) is treated as fixed, and not as a consequence of development strategy or design. In this book there is a strong focus on impact of study design on PoS and ultimately on the value of portfolio. Design options that are discussed in different chapters are dose-selection strategies, adaptive design and enrichment. Some development strategies that are discussed are indication sequencing, optimal number of programs and optimal decision criteria.

This book includes chapters written by authors with very broad backgrounds including financial, clinical, statistical, decision sciences, commercial and regulatory. Many authors have long held executive positions and have been involved with decision making at a product or at a portfolio level. As such, it is expected that this book will attract a very broad audience, including decision makers in pharmaceutical R&D, commercial and financial departments. The intended audience also includes portfolio planners and managers, statisticians, decision scientists and clinicians.

Early chapters describe approaches to portfolio optimization from big Pharma and Venture Capital standpoints. They have stronger focus on finances and processes. Later chapters present selected statistical and decision analysis methods for optimizing drug development programs and portfolios. Some methodological chapters are technical; however, with a few exceptions they require a relatively basic knowledge of statistics by a reader.

Gesamtwerk

Die 8. Auflage ist wieder auf sechs Bände angelegt. Darin finden sich übersichtlich und in systematischer Gliederung Vertragsmuster aus der Feder erfahrener Experten. Jedem dieser Muster folgen Anmerkungen, mit denen der dem Vertragsentwurf zu Grunde liegende Sachverhalt und die Gründe für die Wahl des spezifischen Formulars erläutert werden.

Autoren

  • Dieses Set enthält folgende Produkte:
      Auch in folgendem Set erhältlich:
      • nach oben

        Ihre Daten werden geladen ...